JP Morgan Chase
ATNM icon

JP Morgan Chase’s Actinium Pharmaceuticals ATNM Stock Holding History

JP Morgan Chase’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.48K Hold
1,494
– – ﹤0.01% 7071
2025
Q4 		$2.03K Sell
1,494
-68
-4% -$99 ﹤0.01% 6943
2025
Q3 		$2.5K Sell
1,562
-17,055
-92% -$27.8K ﹤0.01% 6874
2025
Q2 		$26.1K Sell
18,617
-2,507
-12% -$3.75K ﹤0.01% 6112
2025
Q1 		$34K Sell
21,124
-102,707
-83% -$130K ﹤0.01% 5999
2024
Q4 		$156K Buy
123,831
+110,141
+805% +$171K ﹤0.01% 5581
2024
Q3 		$25.7K Sell
13,690
-205
-1% -$810 ﹤0.01% 6180
2024
Q2 		$103K Buy
13,895
+2,111
+18% +$17.4K ﹤0.01% 5504
2024
Q1 		$92.3K Sell
11,784
-6,788
-37% -$43.6K ﹤0.01% 5706
2023
Q4 		$94.3K Buy
18,572
+452
+2% +$2.33K ﹤0.01% 5760
2023
Q3 		$107K Sell
18,120
-2,048
-10% -$13.6K ﹤0.01% 5433
2023
Q2 		$150K Buy
+20,168
New +$172K ﹤0.01% 5255
2016
Q2 		– Sell
-3
Closed – – 4757
2016
Q1 		$0 Buy
+3
New +$189 ﹤0.01% 4648

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase's ATNM Position: Q1 2026 in Review

JP Morgan Chase held its Actinium Pharmaceuticals (ATNM) position steady in Q1 2026 at 1,494 shares worth $1.48K. The position accounts for ﹤0.01% of the portfolio, ranked #7071.

JP Morgan Chase first reported a position in ATNM in Q1 2016 and has held it in 13 quarters since. The position peaked at $156K in Q4 2024. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • JP Morgan Chase held 1,494 shares of Actinium Pharmaceuticals worth $1.48K as of Q1 2026.
  • JP Morgan Chase left its Actinium Pharmaceuticals share count unchanged in Q1 2026.
  • Actinium Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7071 holding.
  • JP Morgan Chase first reported a position in Actinium Pharmaceuticals in Q1 2016 and has held it in 13 quarters since.
  • JP Morgan Chase's Actinium Pharmaceuticals position peaked at $156K in Q4 2024.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.